Finance

Medical device firm Circassia reports revenue rise

Published by
Sam Pither

Circassia, the Oxford-based medical device company which develops devices to diagnose and manage asthma, has announced its unaudited financial figures for the six months ended 30 June.

During this period, the firm made unaudited revenues of approximately £15.5 million, which is 6 per cent more than the same period last year. Once non-recurring loses and gains are deducted this leaves an underlying revenue of 11 per cent.

Underlying earnings are distinct from statutory earnings, which businesses are required to submit by law. They represent the earnings a company has made once non-recurring costs and one-off losses and gains are removed, giving a more accurate depiction of year-on-year financial strength.

Despite the impact of China’s Covid lockdowns, Circassia’s underlying clinical earnings have grown 12 per cent, to an approximate £13 million. This is compared to H1 2021’s £11.6 million, excluding a one-off revenue item of £600,000.

Meanwhile, research revenues, which were up against a strong H1 performance in 2021, were ahead by 4 per cent to £2.5 million.

Read more - Oxford crop protection startup completes £35m round of funding

Part of the reason for these increases may be down to a change in business model. The firm claims its distributer-led sales strategy has led to a reduction in overheads from £10 million in H1 2021 to around £7.8 million.

Another contributing factor is the recent FDA-approval of Beyond Air's LungFit, for which the company is due to receive payments of $10.5 million (~£8.5 million) over the next three years along with up to a further $6 million (~£4.8 million) in royalty payments.

Ian Johnson, Circassia's Executive Chairman, said: "I am pleased to be able to report continued growth in revenues and profits in the year to date. The Company continues to benefit from a high degree of recurring revenues and is trading very profitably and generating cash.

“Future revenue growth is likely to be driven by success in raising the awareness of the benefits of FeNO testing and continued expansion of our worldwide network of distributors. The Company is now in a strong financial position to continue to invest in these areas and is making good progress. I look forward to updating shareholders again at the time of the half-year results."

Read more - Business Magazine oil painting auction in aid of Ukraine reaches £5k

Sam Pither

Sam is the Regional Editor of Biz News, responsible for both Hampshire and Dorset. A new recruit to journalism, Sam started writing for the Business Magazine as a freelancer in May of 2022 after completing his degree in English at University College London. His passion for local businesses and ability to tell a story soon caught the attention of the publication’s management team and have led to his meteoric rise. Sam, who lives in central Reading, takes a particular interest in technology, gaming and food and drink, having been a chef before starting his degree.

Recent Posts

Halma acquires safety tech firm MK Test in £44m deal

Buckinghamshire tech company Halma has acquired transport safety firm MK Test Systems Limited. Headquartered in…

5 hours ago

Paragon Bank provides finance for West Sussex housing development

BRiCS Development has secured an £11.55 million finance facility with Paragon Bank’s Development Finance team…

6 hours ago

IT firm Mintivo appoints new Managing Director

IT services and solutions company Mintivo has appointed Alex Jukes as its new Managing Director…

6 hours ago

Bartlett Tree Experts to build new research facility in Wokingham woodland

Bartlett Tree Experts have announced its intention to build a new arboretum and research facility…

6 hours ago

New £3m imaging system to be developed at University of Surrey

The creation of a first-of-its-kind imaging system at the University of Surrey could help the…

6 hours ago

New chair of trustees at Open Sight Hampshire

Open Sight, which provides support across Hampshire to those living with or at risk of…

8 hours ago